PortfoliosLab logo

Global X China Biotech Innovation ETF (CHB)

ETF · Currency in USD · Last updated Jun 24, 2022

CHB is a passive ETF by Global X tracking the investment results of the Solactive China Biotech Innovation Index. CHB launched on Sep 22, 2020 and has a 0.67% expense ratio.

ETF Info

ISINUS37954Y2515
CUSIP37954Y251
IssuerGlobal X
Inception DateSep 22, 2020
RegionGlobal ex-U.S. (Broad)
CategoryInnovation, China Equities, Health & Biotech Equities
Expense Ratio0.67%
Index TrackedSolactive China Biotech Innovation Index
ETF Home Pagewww.globalxetfs.com
Asset ClassEquity

Asset Class Size

Multi-Cap

Asset Class Style

Blend

Trading Data

Previous Close$10.60
Year Range$9.26 - $19.15
EMA (50)$10.20
EMA (200)$12.96
Average Volume$898.80

CHBShare Price Chart


Chart placeholderClick Calculate to get results

CHBPerformance

The chart shows the growth of $10,000 invested in Global X China Biotech Innovation ETF on Sep 28, 2020 and compares it to the S&P 500 index or another benchmark. It would be worth nearly $6,955 for a total return of roughly -30.45%. All prices are adjusted for splits and dividends.


CHB (Global X China Biotech Innovation ETF)
Benchmark (^GSPC)

CHBReturns in periods

Returns over 1 year are annualized

PeriodReturnBenchmark
1M6.11%-4.48%
YTD-25.09%-19.05%
6M-27.61%-17.85%
1Y-42.53%-9.15%
5Y-19.05%9.03%
10Y-19.05%9.03%

CHBMonthly Returns Heatmap


Chart placeholderClick Calculate to get results

CHBSharpe Ratio Chart

The Sharpe ratio shows whether the portfolio's excess returns are due to smart investment decisions or a result of taking a higher risk. The higher a portfolio's Sharpe ratio, the better its risk-adjusted performance.

The current Global X China Biotech Innovation ETF Sharpe ratio is -1.24. A negative Sharpe ratio means that the risk-free rate is higher than the portfolio's return. This value does not convey any meaningful information.

The chart below displays rolling 12-month Sharpe Ratio.


CHB (Global X China Biotech Innovation ETF)
Benchmark (^GSPC)

CHBDividend History


Global X China Biotech Innovation ETF doesn't pay dividends

CHBDrawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


CHB (Global X China Biotech Innovation ETF)
Benchmark (^GSPC)

CHBWorst Drawdowns

The table below shows the maximum drawdowns of the Global X China Biotech Innovation ETF. A maximum drawdown is an indicator of risk. It shows a reduction in portfolio value from its maximum due to a series of losing trades.

The maximum drawdown since January 2010 for the Global X China Biotech Innovation ETF is 53.91%, recorded on Apr 26, 2022. The portfolio has not recovered from it yet.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-53.91%Feb 17, 2021297Apr 26, 2022
-10.8%Oct 14, 202042Dec 11, 202015Jan 5, 202157
-6.83%Jan 26, 20214Jan 29, 20213Feb 3, 20217
-1.74%Jan 11, 20211Jan 11, 20211Jan 12, 20212
-0.89%Jan 13, 20211Jan 13, 20211Jan 14, 20212
-0.85%Oct 2, 20201Oct 2, 20201Oct 5, 20202
-0.8%Feb 4, 20211Feb 4, 20211Feb 5, 20212
-0.62%Jan 7, 20211Jan 7, 20211Jan 8, 20212
-0.47%Jan 15, 20211Jan 15, 20211Jan 19, 20212
-0.23%Sep 28, 20201Sep 28, 20201Sep 29, 20202

CHBVolatility Chart

Current Global X China Biotech Innovation ETF volatility is 37.22%. The chart below shows the rolling 10-day volatility. Volatility is a statistical measure showing how big price swings are in either direction. The higher asset volatility, the riskier it is, because the price movements are less predictable.


CHB (Global X China Biotech Innovation ETF)
Benchmark (^GSPC)

Portfolios with Global X China Biotech Innovation ETF


Loading data...